Vaccination protects against acute respiratory distress syndrome (ARDS) in hospitalized patients with COVID-19.

Publication date: Jan 27, 2024

This study aimed to analyze the effect of COVID-19 vaccination on the occurrence of ARDS in hospitalized COVID-19 patients. The study population of this retrospective, single-center cohort study consisted of hospitalized COVID-19 patients with known vaccination status and chest computed tomography imaging between July 2021 and February 2022. The impact of vaccination on ARDS in COVID-19 patients was assessed through logistic regression adjusting for demographic differences and confounding factors with statistical differences determined using confidence intervals and effect sizes. A total of 167 patients (69% male, average age 58 years, 95% CI [55; 60], 42% fully vaccinated) were included in the data analysis. Vaccinated COVID-19 patients had a reduced relative risk (RR) of developing ARDS (RR: 0. 40, 95% CI [0. 21; 0. 62]). Consequently, non-vaccinated hospitalized patients had a 2. 5-fold higher probability of developing ARDS. This risk reduction persisted after adjusting for several confounding variables (RR: 0. 64, 95% CI [0. 29; 0. 94]) in multivariate analysis. The protective effect of COVID-19 vaccination increased with ARDS severity (RR: 0. 61, 95% CI [0. 37; 0. 92]). Particularly, patients under 60 years old were at risk for ARDS onset and seemed to benefit from COVID-19 vaccination (RR: 0. 51, 95% CI [0. 20; 0. 90]). COVID-19 vaccination showed to reduce the risk of ARDS occurrence in hospitalized COVID-19 patients, with a particularly strong effect in patients under 60 years old and those with more severe ARDS.

Concepts Keywords
58years ARDS
July COVID-19
Tomography Hospitalization
Vaccinated Vaccination

Semantics

Type Source Name
disease VO vaccination
disease MESH acute respiratory distress syndrome
disease MESH COVID-19
disease VO population
disease VO vaccinated

Original Article

(Visited 1 times, 1 visits today)